Published in BMC Res Notes on July 26, 2015
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
[Immunotherapy as modern tumor treatment]. Radiologe (2017) 0.75
Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab (2002) 13.06
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg (2011) 2.21
Prostate cancer may trigger paraneoplastic limbic encephalitis: a case report and a review of the literature. Int J Urol (2012) 1.59
Hashimoto's encephalopathy. Ann N Y Acad Sci (2008) 1.57
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol (2010) 1.33
Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res (2012) 1.08
Paraneoplastic neurological and hematological syndromes associated with prostate cancer. Int J Urol (2012) 0.92
Neurological immune-related adverse events of ipilimumab. Pract Neurol (2013) 0.91
Pearls & oy-sters: Hashimoto encephalopathy. Neurology (2012) 0.87